You are here: Industry Insights > Market News > Ono Pharma submits marketing approval of metyrosine in Japan

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

Ono Pharma submits marketing approval of metyrosine in Japan

biospectrumasiaMay 03, 2018

Tag: Ono Pharmaceutical , metyrosine , Japan , Valeant

Favorites

Japanese drugmaker Ono Pharmaceutical has submitted a new drug application for the approval of pheochromocytoma (PCC) treatment metyrosine (ONO-5371), a tyrosine hydroxylase inhibitor licensed from Canada’s Valeant Pharmaceuticals International in October 2013, in Japan.

This application is based on a multicenter, open-label, non-comparative study and its accompanying continuous administration study, Phase I/II study (ONO-5371-02), in patients with the symptoms associated with catecholamine excess secretion of pheochromocytoma, conducted in Japan.

Valeant markets metyrosine under the trade name of Demser in the indication of PCC

Register as Visitor to CPhI China 2018!

Previous:Samsung BioLogics’ stock slides after regulators claim accounting rules infraction

Next:India’s drug regulatory force conducts third round of raids on manufacturers

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Ono Pharma submits marketing approval of metyrosine in Japan | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Stephania japonica extract Japanese Stephania Root extract Tabellae Cepharanthini extract

Desiccants use Japanese papaer

Japanese Pagodatree Flower-bud

Gallic acid Japanese enterprise standard

American standard Japanese standard German standard gate valve

Organic Ceremonial Green Japanese Face Instant Greentea Grade Halal Pure Oem Japan Matcha Tea Powder

Stephania japonica extract Japanese Stephania Root extract Tabellae Cepharanthini extract Rotundine

Ceremonial Green Japanese Face Instant Greentea Grade Halal Pure Oem Japan Organic Matcha Tea Powder

Desiccant use Japanese Paper

PHENOXYMETHYL PENICILLIN POTASSIUM

Ono Pharma submits marketing approval of metyrosine in Japan

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>